Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials
In the SAKK 09/10 and RTOG 0126 randomized controlled trials, we demonstrated that PORTOS can potentially identify a subset of patients who benefit from DE, a subgroup that cannot be identified using clinicopathological or prognostic variables. These results suggest that PORTOS could be used clinically as a predictor of radiation response.
Authors
- E. Davicioni
- A. Dal Pra
- Corinne Schär
- D.E. Spratt
- H.M. Sandler
- Tobias Hölscher (ORCID: https://orcid.org/0000-0002-9991-6152)
- G.N. Thalmann
- Paul Linh Nguyen (ORCID: https://orcid.org/0000-0003-4268-3973)
- Matthew Parliament (ORCID: https://orcid.org/0000-0002-5091-9344)
- Pirus Ghadjar (ORCID: https://orcid.org/0000-0002-2747-165X)
- Bülent Polat (ORCID: https://orcid.org/0000-0003-4677-424X)
- Theodore Karrison (ORCID: https://orcid.org/0009-0009-8641-5111)
- Rohann Correa (ORCID: https://orcid.org/0000-0003-0886-1625)
- Jason A. Efstathiou (ORCID: https://orcid.org/0000-0003-0996-0350)
- Hyunnam Ryu (ORCID: https://orcid.org/0000-0002-8408-703X)
- Walter A. Hall
- Stefanie Hayoz (ORCID: https://orcid.org/0000-0002-2265-6559)
- L. Plasswilm
- J.A. Proudfoot
- John M. Robertson
- Alan Pollack (ORCID: https://orcid.org/0000-0002-1801-2865)
- Daniel R. Zwahlen (ORCID: https://orcid.org/0000-0003-4359-7735)
- Shuang George Zhao (ORCID: https://orcid.org/0000-0002-9166-6507)
- Guido Hildebrandt (ORCID: https://orcid.org/0000-0002-0498-2692)
- D.M. Aebersold
- Ian S. Dayes (ORCID: https://orcid.org/0000-0001-8550-1485)
- Alejandro Berlín (ORCID: https://orcid.org/0000-0002-1880-6905)
- P.T. Tran
- Yang Liu (ORCID: https://orcid.org/0000-0002-0367-8189)
- J.M. Michalski
- J Simko
- Arndt-Christian Mueller
- F.Y. Feng
Institutions
- University of Bern (CH)
- University of Maryland, Baltimore (US)
- Cedars-Sinai Medical Center (US)
- University Health Network (CA)
- University of Wisconsin–Madison (US)
- University of Alberta (CA)
- University of California, San Francisco (US)
- Medical College of Wisconsin (US)
- Washington University in St. Louis (US)
- Juravinski Cancer Centre (CA)
- Kantonsspital St. Gallen (CH)
- London Health Sciences Centre (CA)
- University Hospital of Bern (CH)
- Princess Margaret Cancer Centre (CA)
- Massachusetts General Hospital (US)
- Kantonsspital Winterthur (CH)
- Dana-Farber Cancer Institute (US)
- University Hospitals Seidman Cancer Center (US)
- Veracyte (United States) (US)
- Universitätsklinikum Würzburg (DE)
- Beaumont Hospital, Royal Oak (US)
- Swiss Group For Clinical Cancer Research (CH)
- Sylvester Comprehensive Cancer Center (US)
- University Hospital Carl Gustav Carus (DE)
- NRG Oncology (US)
- University of Rostock (DE)
- Case Western Reserve University (US)
- Hamilton Health Sciences (CA)
- Charité - Universitätsmedizin Berlin (DE)
- University of Tübingen (DE)
Publication Details
- Journal
- Annals of Oncology
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1016/j.annonc.2025.01.017
- Citations
- 7
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 10.63
Funders
- U.S. Department of Defense
- NRG Oncology
- Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung
- National Institutes of Health
- National Cancer Institute